Miranda Kleijn, PhD, Agendia, Amsterdam, Netherlands, discusses the FLEX study (NCT03053193), a large-scale, prospective, observational trial of patients with stage I-III breast cancer. FLEX aims to create a global registry that links comprehensive clinical and full genome expression data to elucidate new prognostic and/or predictive gene associations. The dataset will record linked genomic and clinical data, with over 800 data points for each patient over a 10-year follow-up period. Over 6000 patients are registered to date, with continuing enrollment worldwide. FLEX investigator-initiated substudies have resulted in 18 published abstracts. The real-world dataset brings great opportunities for novel genomic discoveries to aid the growth of precision oncology. This interview took place during the 17th St. Gallen International Breast Cancer Conference.